Strengthening Oligonucleotide Capabilities: Zelmic Invests in Advanced UHPLC Technology
March 18, 2026
Zelmic continues to expand its capabilities in advanced topical and transdermal drug development with a strategic investment in state-of-the-art analytical instrumentation: the Vanquish™ Horizon UHPLC System (integrated biocompatible system).
This investment marks an important step in supporting the growing demand for oligonucleotide-based therapeutics, including siRNA and other nucleic acid modalities.
Enabling the Next Generation of Topical Therapeutics
Oligonucleotides such as siRNA are rapidly emerging as highly specific therapeutic tools, offering targeted gene silencing for a range of dermatological and systemic indications. However, their development presents unique challenges related to:
- Molecular stability
- Skin penetration and delivery
- Complex analytical requirements
Accurate and sensitive analytical methods are therefore essential to ensure product quality, stability, and performance throughout development
Advanced UHPLC for High-Precision Oligonucleotide Analysis
The newly installed Vanquish™ Horizon UHPLC System is specifically designed for biocompatible and high-resolution analysis of biomolecules, making it ideally suited for oligonucleotide characterization.
With this system, Zelmic can offer:
- High-sensitivity quantification of oligonucleotides
- Improved separation of structurally similar species and impurities
- Robust and reproducible analytical performance
- Compatibility with complex biological and formulation matrices
This significantly strengthens our ability to support cutting-edge drug development projects involving nucleic acids and other sensitive molecules.
Supporting Complex Formulation Development
The development of topical products containing large, sensitive molecules such as oligonucleotides requires a deep understanding of both formulation science and skin barrier function.
The skin’s outer layer—the stratum corneum—represents a major barrier to large and hydrophilic molecules, making delivery particularly challenging.
To address this, advanced formulation strategies such as nanoparticle systems, lipid carriers, and follicular targeting approaches are increasingly being explored.
At Zelmic, we combine:
- Formulation development expertise
- In vitro performance testing (IVRT/IVPT)
- Analytical method development
- GMP manufacturing capabilities
to support the successful development of these complex products.
Driving Innovation in Drug Delivery
This investment reflects Zelmic’s continued commitment to advancing innovative drug delivery solutions and staying at the forefront of pharmaceutical development.
As interest in oligonucleotide-based therapies grows, so does the need for specialized expertise and infrastructure.
Zelmic is proud to be part of that progress.
👉 Learn more about our services: https://zelmic.se/product-development/
👉 Contact us to discuss your project: https://zelmic.se/contact/
